EVAX
Evaxion Biotech A/S
There isn't enough reported data to score EVAX yet.
EVAX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
EVAX's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
EVAX PE Valuation
EVAX has no meaningful PE right now: it lost money over the past year.
EVAX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect EVAX's losses to grow, with revenue declining.
EVAX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2022 | -$44.36 | -$0.32 |
| Q1 2022 | -$50.76 | -$13.52 |
| Q4 2021 | -$49.96 | -$15.48 |
| Q3 2021 | -$45.04 | -$13.76 |
EVAX is still losing money, but far less than before: $4.89 per share over the past year, against $50.76 at its worst in early 2022.
EVAX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $7.5M | +139% |
| Q2 2025 | $37K | -76% |
| Q4 2024 | $3.1M | +4200% |
EVAX's revenue is growing: $7M last quarter, up 4764% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -14% | +2961 points |
| Q2 2025 | -11730% | -3110 points |
| Q4 2024 | -183% | N/A |
| Q2 2024 | -2975% | N/A |
| Q1 2024 | -8620% | N/A |
| Q4 2023 | -5978% | N/A |
EVAX's operating margin was −14% last quarter, up 8606 points from the same quarter a year ago.
EVAX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2025 | $0 | $0 |
| Q1 2025 | $0 | $0 |
| Q4 2024 | -$4M | -$1.9M |
| Q2 2024 | $0 | $0 |
| Q1 2024 | $0 | $0 |
| Q4 2023 | -$2M | +$3.8M |
| Q3 2023 | -$4.5M | +$2.2M |
| Q2 2023 | $0 | +$5.3M |
EVAX has burned cash in most quarters: −$4M over the past year, against −$6M the year before.
EVAX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +62% | +422K shares |
| 3 years | +104% | +563K shares |
| 5 years | +130% | +625K shares |
EVAX has 1M diluted shares, up 62% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q1 2025 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
EVAX Net Leverage
EVAX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
EVAX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.9 | Neutral |
| Stochastic | 11.2 | Oversold |
EVAX's weekly RSI is 43 (neutral) and its Stochastic is 11 (oversold).
EVAX PE vs Healthcare Sector
EVAX has no meaningful PE right now: it lost money over the past year.
EVAX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.11 | 11% below |
| 20 week MA | $3.13 | 12% below |
| 50 week MA | $3.68 | 25% below |
| 100 week MA | $3.47 | 20% below |
| 200 week MA | $20.3 | 86% below |
EVAX is in a downtrend: it's below all five of its weekly moving averages, and 86% below its 200-week average.
EVAX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $494.5 | $207.5 | -58% |
| 2022 | $207.5 | $86.5 | -58% |
| 2023 | $86.5 | $34.3 | -60% |
| 2024 | $34.3 | $5.30 | -85% |
| 2025 | $5.30 | $5.13 | -3.2% |
| 2026 YTD | $5.13 | $2.77 | -46% |
EVAX has finished every year since 2021 lower, and it's down 46% so far in 2026.